Second Indication for Ibrance

March 7, 2016

Second Indication for Ibrance

IBRANCE (palbociclib) was recently granted F.D.A.-approval for a second indication.

IRBANCE is a limited distribution oral oncology medication approved for use in certain types of breast cancer patients.  As a limited distribution medication, IBRANCE is only available from a handful of select pharmacies

Onco360 has access to IBRANCE and the product is immediately available for prescription order.  Order IBRANCE now.

For more information visit our IBRANCE page.